Welcome to our dedicated page for Biomea Fusion SEC filings (Ticker: BMEA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Access the complete archive of SEC filings for Biomea Fusion Inc (NASDAQ: BMEA), a clinical-stage biopharmaceutical company developing oral therapies for diabetes and obesity. SEC filings provide the most authoritative source of information about the company's financial condition, clinical progress, risk factors, and business strategy. These regulatory disclosures are essential for conducting thorough due diligence on BMEA stock.
Key filing types include Form 10-K annual reports, which offer detailed analysis of the company's business operations, clinical trial results, intellectual property portfolio, competitive landscape, and audited financial statements. Form 10-Q quarterly reports provide updates on trial enrollment, cash burn rate, research and development expenses, and material developments that occurred during the quarter. Form 8-K current reports disclose material events such as clinical trial results, financing activities, partnership agreements, or significant corporate changes as they occur.
For clinical-stage biotech companies like Biomea Fusion, the Management's Discussion and Analysis sections in 10-K and 10-Q filings are particularly valuable. These sections explain the company's clinical development strategy, trial timelines, regulatory pathway, and management's assessment of capital requirements. The Risk Factors section outlines potential challenges including clinical trial failures, regulatory setbacks, competitive threats, and financial risks. Proxy statements (DEF 14A) reveal executive compensation, board composition, and governance matters.
Registration statements and prospectuses related to equity offerings detail the terms of capital raises and dilution to existing shareholders. Investors tracking BMEA should monitor filings for updates on clinical trial progress, changes in cash position, partnership developments, and any modifications to the company's development priorities. This comprehensive filing archive enables investors to access the primary source documents that drive investment decisions in BMEA stock.
Biomea Fusion, Inc. executive and director Rainer M. Erdtmann reported buying 30,000 shares of Biomea Fusion common stock on 12/11/2025 at a weighted-average price of $1.4333 per share. After this transaction, he directly owns 723,027 shares.
Erdtmann also reports indirect holdings, including 19,400 shares held by a daughter, 20,000 shares held by a son, 20,000 shares held by another daughter, and additional shares held in two independent trusts and two Point Sur investment entities where he has voting or dispositive power but disclaims beneficial ownership beyond any pecuniary interest. He serves as President, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer, and a director of Biomea Fusion. The 30,000-share purchase was executed in multiple trades between $1.42 and $1.46 per share.
Biomea Fusion, Inc. (BMEA) filed its Q3 2025 report, highlighting reduced operating spend and liquidity pressure. The company reported a Q3 net loss of $16.4 million and basic/diluted loss per share of $0.27. Operating expenses fell to $20.8 million, driven by lower research and development costs, while interest and other income was $4.4 million.
Cash, cash equivalents and restricted cash were $47.0 million as of September 30, 2025. The filing states there is substantial doubt about the company’s ability to continue as a going concern, absent additional financing. A $2.2 million non‑cash impairment was recorded after ceasing laboratory use for R&D. A warrant liability of $17.9 million reflects the fair value of common warrants issued in June 2025.
To bolster liquidity, the company completed public offerings in June and on October 6, 2025, with the October transaction generating approximately $25.0 million in gross proceeds. Shares outstanding were 59,508,518 as of September 30, 2025 and 70,703,639 as of October 31, 2025. Clinical programs continue, including Phase II trials of icovamenib in diabetes and the IND‑cleared BMF‑650 with an ongoing Phase I trial.
Biomea Fusion, Inc. (BMEA) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 to a current report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The company notes that the information provided under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act.
This amendment reports that a Cormorant investment group and director Bihua Chen together hold a meaningful minority stake in Biomea Fusion, Inc. The filing discloses group-wide shared voting and dispositive power over 3,570,872 shares, equal to
The percentage calculations use a post-offering share count of 69,322,377 common shares as stated in the filing materials. The filing also notes there were no transactions in the issuer's securities by the reporting persons during the sixty-day period before this statement, and it updates identity, citizenship, and source-of-funds information for the reporting entities.
Biomea Fusion, Inc. filed an Form 8-K reporting several exhibits tied to a securities offering and related legal opinions. The filing lists an Underwriting Agreement dated
Biomea Fusion, Inc. (BMEA) is offering common shares together with accompanying common stock warrants or pre-funded warrants at a combined public offering price of
Proceeds are intended to fund the Phase IIb development of Icovamenib in type 2 diabetes and clinical development of the oral GLP-1 receptor agonist candidate BMF-650, plus general corporate purposes. The prospectus notes limited liquidity for the warrants (no listing expected) and lock-up agreements restricting certain insiders for 60 days. Tax and transfer mechanics for non-U.S. holders and exercise limitations are described; holders have no stockholder rights until exercise.
Biomea Fusion, Inc. (BMEA) is offering shares of common stock together with accompanying common stock warrants (and pre-funded warrants in lieu thereof) as described in this prospectus supplement. The offering is included within up to $300.0 million of shares that may be sold under the accompanying prospectus. Each common stock warrant will be exercisable immediately, has an initial exercise price subject to adjustment, and will expire three years from issuance. The company intends to use net proceeds, together with existing cash, to fund the Phase IIb development of Icovamenib in type 2 diabetes and clinical development of its oral GLP-1 receptor agonist candidate, BMF-650, for obesity and diabetes, plus general corporate purposes. The prospectus notes that the warrants (including pre-funded warrants) are not expected to be listed, limiting liquidity, and that exercise of pre-funded warrants is typically cashless (exercise price $0.0001). The document highlights potential dilution from future equity issuances, lock-up agreements with possible early releases, and U.S. and non-U.S. tax and withholding considerations for holders.
Biomea Fusion, Inc. reporting persons disclosed their beneficial ownership of the company’s common stock. The filing shows that Rainer M. Erdtmann beneficially owns an aggregate of 2,975,224 shares, representing approximately 5.2% of the outstanding class on the basis reported. That total includes 482,404 shares issuable upon exercise of options exercisable within 60 days plus directly held shares and shares held in trusts and for family members.
Related entities Point Sur Investors, LLC and Point Sur Investors Fund I, L.P. directly hold 252,320 and 228,470 shares, respectively (a combined 480,790 shares), over which Mr. Erdtmann has shared voting and dispositive power as the managing member and general partner.
Michael J.M. Hitchcock, who serves as Interim CEO and a director of Biomea Fusion, Inc. (BMEA), was granted a stock option giving him the right to purchase 916,434 shares of common stock at an exercise price of $1.53 per share. The option vests in 16 substantially equal quarterly installments beginning after August 8, 2025 and will be fully vested on August 8, 2029, subject to continued service. The option expires on August 10, 2035 and is reported as directly beneficially owned.
This filing records an executive equity award with a multiyear vesting schedule and a single stated exercise price; the form does not disclose total outstanding shares, prior holdings for this reporting person, or cashless-exercise provisions, so the potential dilution or relative size of the grant cannot be determined from this document alone.
FAQ
What is the current stock price of Biomea Fusion (BMEA)?
What is the market cap of Biomea Fusion (BMEA)?
